Section Edited by Claudia Palena, PhD and Eric Tartour, MD, PhD
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, and other combination treatments with the anti-tumor immune response.
Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironmentPengfei Xu, Joy C Yang, Bo Chen, Christopher Nip, Jonathan E Van Dyke, Xiong Zhang, Hong-Wu Chen, Christopher P Evans, William J Murphy, Chengfei Liu
5 May 2023
Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progressionJiuhui Xu, Qianyu Shi, Jingbing Lou, Boyang Wang, Wei Wang, Jianfang Niu, Lei Guo, Chenglong Chen, Yiyang Yu, Yi Huang, Wei Guo, Jianqiang Lan, Yu Zhu, Tingting Ren, Xiaodong Tang
25 April 2023
YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6Saisai Chen, Kai Lu, Yue Hou, Zonghao You, Chuanjun Shu, Xiaoying Wei, Tiange Wu, Naipeng Shi, Guangyuan Zhang, Jianping Wu, Shuqiu Chen, Lihua Zhang, Wenchao Li, Dingxiao Zhang, Shenghong JuSee the full list of authors
24 April 2023
Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancerMiao He, Qihua He, Xiuyu Cai, Jun Liu, Hongshen Deng, Feng Li, Ran Zhong, Yi Lu, Haoxin Peng, Xiangrong Wu, Zisheng Chen, Shen Lao, Caichen Li, Jianfu Li, Jianxing HeSee the full list of authors
18 April 2023
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cellsMary J van Helden, Seline A Zwarthoff, Roel J Arends, Inge M J Reinieren-Beeren, Marc C B C Paradé, Lilian Driessen-Engels, Karin de Laat-Arts, Désirée Damming, Ellen W H Santegoeds-Lenssen, Daphne W J van Kuppeveld, Imke Lodewijks, Hugo Olsman, Hanke L Matlung, Katka Franke, Ellen Mattaar-HeppSee the full list of authors
17 April 2023
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanomaLuiza Martins Nascentes Melo, Dayana Herrera-Rios, Daniel Hinze, Stefanie Löffek, Irem Oezel, Roberta Turiello, Juliane Klein, Sonia Leonardelli, Isa-Vanessa Westedt, Yahya Al-Matary, Sara Egea-Rodriguez, Alexandra Brenzel, Maja Bau, Antje Sucker, Eva HadaschikSee the full list of authors
7 April 2023
ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancersZheng-Zheng Yu, Yun-Ya Liu, Wei Zhu, Ding Xiao, Wei Huang, Shan-Shan Lu, Hong Yi, Ting Zeng, Xue-Ping Feng, Li Yuan, Jie-Ya Qiu, Di Wu, Qi Wen, Jian-Hua Zhou, Wei ZhuangSee the full list of authors
31 March 2023
Identification of HPV16 E1 and E2-specific T cells in the oropharyngeal cancer tumor microenvironmentChristine McInnis, Shilpa Bhatia, Brinda Vijaykumar, Qiaomu Tian, Yanbo Sun, Del Leistritz-Edwards, Charles T Quinn, Ravi Uppaluri, Ann Marie Egloff, Lakshmi Srinivasan, Daniel C Pregibon, Anthony J Coyle, Glenn J Hanna
29 March 2023
Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapyRasmus Erik Johansson Mortensen, Morten Orebo Holmström, Thomas Landkildehus Lisle, Jane P Hasselby, Gro L Willemoe, Özcan Met, Inge Marie Svane, Julia Johansen, Dorte L Nielsen, Inna M Chen, Mads Hald Andersen
22 March 2023
Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survivalLuigi D'Antonio, Cristiano Fieni, Stefania Livia Ciummo, Simone Vespa, Lavinia Lotti, Carlo Sorrentino, Emma Di Carlo
16 March 2023